June 16, 2025 06:44 AM EDTUpdated 11:24 AM
R&D

Lil­ly posts en­cour­ag­ing ear­ly-stage weight loss da­ta on amylin can­di­date

Elizabeth Cairns

Senior biopharma journalist

Eli Lil­ly’s un­der-the-radar amylin ana­log al­lowed obese pa­tients in a Phase 1 tri­al to lose up to 11.3% of their body weight. The drug ap­pears …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Sage's roller coast­er ends in $561M ac­qui­si­tion by Su­per­nus

What's com­ing in five years? FDA chief points to uni­ver­sal flu vac­cine, new ap­proval path­way

Ab­b­Vie’s can­cer drug fails Phase 3 com­bo study to treat oth­er bone mar­row dis­eases

For­mer CEO Anne Wo­j­ci­c­ki wins bid for 23andMe

Roche moves ahead with Phase 3 Parkin­son’s study de­spite mixed tri­al re­sults

sponsored

This com­pa­ny has spent a decade in­no­vat­ing NGS-based com­pan­ion di­ag­nos­tics world­wide–what’s next?

A service from the Financial Times